Guardian Partners’s AbbVie ABBV Stock Holding History

Guardian Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$430K	Buy	1,977 +1	+0.1%	+$222	0.04%	150
2025 Q4	$429K	Buy	+1,976	New	+$450K	0.03%	162

Other funds holding ABBV

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Guardian Partners's ABBV Position: Q1 2026 in Review

Guardian Partners increased its AbbVie (ABBV) stake by 0.05% in Q1 2026, buying an estimated $222 and bringing the position to 1,977 shares worth $430K. The position accounts for 0.04% of the portfolio, ranked #150.

Guardian Partners first reported a position in ABBV in Q4 2025 and has held it in 2 quarters since. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Guardian Partners held 1,977 shares of AbbVie worth $430K as of Q1 2026.
Guardian Partners bought 1 AbbVie share in Q1 2026, an estimated $222.
AbbVie made up 0.04% of Guardian Partners's portfolio in Q1 2026, its #150 holding.
Guardian Partners first reported a position in AbbVie in Q4 2025 and has held it in 2 quarters since.
4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Guardian Partners's 13F filing for Q1 2026, filed 18 May 2026.